SynthesisEndocrine2025
Relationship between affected family members and clinical aggressiveness in Familial non-medullary thyroid carcinoma: a systematic review and meta-analysis.
Synthesis in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Clinical characteristics and prognosis of familial non-medullary thyroid carcinoma: a retrospective study of 98 families.World journal of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeThe clinical implications of the number of affected family members in familial non-medullary thyroid carcinoma (FNMTC) remain debated. This meta-analysis aimed to clarify whether families with ≥ 3 affected first-degree relatives (FNMTC-3) exhibit distinct clinicopathologic and prognostic features compared to families with two affected members (FNMTC-2), and to compare these patients with sporadic non-medullary thyroid carcinoma (SNMTC).
methodsFollowing PRISMA guidelines, we systematically searched PubMed, Embase, and Cochrane Library for relevant studies. Meta-analysis was performed using RevMan 5.4 and Stata MP 18 to calculate pooled odds ratios (ORs), mean differences (MDs), and hazard ratios (HRs) with 95% confidence intervals (CIs).
resultsTwenty-one studies involving 3036 FNMTC and 10,497 SNMTC patients were included. Compared to SNMTC, both FNMTC-2 and FNMTC-3 exhibited younger age at diagnosis (MD: -0.81 and − 1.66 years), higher multifocality (OR: 1.48 and 1.91), bilaterality (OR: 1.53 and 1.48), lymph node metastasis (OR: 1.16 and 1.74), distant metastasis (OR: 2.43 and 3.93), and recurrence risks (OR: 1.29 and 1.49). Strikingly, FNMTC-3 demonstrated greater aggressiveness than FNMTC-2, including smaller tumor size (MD=-0.22 cm, p = 0.007) but higher multifocality (OR = 1.26, p = 0.03), bilaterality (OR = 1.40, p = 0.004), lymph node metastasis (OR = 1.48, p = 0.002), distant metastasis risks (OR = 1.97, p = 0.01).
conclusionThe clinical aggressiveness of FNMTC escalates with increasing numbers of affected family members. FNMTC-3 patients require more aggressive treatment and surveillance. While the current diagnostic criterion for FNMTC (≥ 2 affected members) remains clinically valid, families with ≥ 3 affected members should be classified as a high-risk subgroup, warranting individualized management strategies.
Indexed as
Identifiers
40908394What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.